JP2023530978A5 - - Google Patents

Info

Publication number
JP2023530978A5
JP2023530978A5 JP2022577322A JP2022577322A JP2023530978A5 JP 2023530978 A5 JP2023530978 A5 JP 2023530978A5 JP 2022577322 A JP2022577322 A JP 2022577322A JP 2022577322 A JP2022577322 A JP 2022577322A JP 2023530978 A5 JP2023530978 A5 JP 2023530978A5
Authority
JP
Japan
Prior art keywords
adc
genes
subject
marker genes
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022577322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530978A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/037994 external-priority patent/WO2021257938A1/en
Publication of JP2023530978A publication Critical patent/JP2023530978A/ja
Publication of JP2023530978A5 publication Critical patent/JP2023530978A5/ja
Pending legal-status Critical Current

Links

JP2022577322A 2020-06-19 2021-06-18 抗体薬物複合体（ａｄｃ）によるがんの治療のための方法に使用するためのマーカー Pending JP2023530978A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063041636P 2020-06-19 2020-06-19
US63/041,636 2020-06-19
PCT/US2021/037994 WO2021257938A1 (en) 2020-06-19 2021-06-18 Markers for use in methods for treating cancers with antibody drug conjugates (adc)

Publications (2)

Publication Number Publication Date
JP2023530978A JP2023530978A (ja) 2023-07-20
JP2023530978A5 true JP2023530978A5 (https=) 2024-06-24

Family

ID=79171607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577322A Pending JP2023530978A (ja) 2020-06-19 2021-06-18 抗体薬物複合体（ａｄｃ）によるがんの治療のための方法に使用するためのマーカー

Country Status (12)

Country Link
US (1) US20230270871A1 (https=)
EP (1) EP4168039A4 (https=)
JP (1) JP2023530978A (https=)
KR (1) KR20230040989A (https=)
CN (1) CN116209464A (https=)
AU (1) AU2021292566A1 (https=)
CA (1) CA3185666A1 (https=)
IL (1) IL299085A (https=)
MX (1) MX2022016232A (https=)
PH (1) PH12022553333A1 (https=)
TW (1) TW202214304A (https=)
WO (1) WO2021257938A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
MX2024001834A (es) * 2021-08-13 2024-05-15 Agensys Inc Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12.
WO2024211893A2 (en) * 2023-04-07 2024-10-10 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2025208105A1 (en) * 2024-03-29 2025-10-02 Pyxis Oncology, Inc. Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders
CN120738285B (zh) * 2025-07-03 2026-03-31 北京石油化工学院 一种具有提升cho外源蛋白表达量的新型质粒载体及其构建和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0820819B1 (pt) * 2007-12-21 2021-06-08 F. Hoffmann-La Roche Ag formulação de anticorpos humanizados b-ly 1 e seu uso
MX347954B (es) * 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
MX2015014486A (es) * 2013-04-15 2016-07-21 Regeneron Pharma Marcadores de respuesta de células tumorales a la terapia.
EP3347048B1 (en) * 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
US11273155B2 (en) * 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
WO2018226578A1 (en) * 2017-06-05 2018-12-13 Agensys, Inc. Nectin-4-binding proteins and methods of use thereof
TW202003047A (zh) * 2018-03-23 2020-01-16 美商西雅圖遺傳學公司 包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
AU2019392090A1 (en) * 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2023530978A5 (https=)
AU2013312868B2 (en) Methods for treating atopic dermatitis by administering an IL-4R antagonist
US11795216B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
JP2022033891A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
JP2021528423A5 (https=)
FI3810281T3 (fi) Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla
TW202003047A (zh) 包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
JP2015534579A5 (https=)
JP2021501776A5 (https=)
JP2022513684A5 (https=)
CA3185666A1 (en) Markers for use in methods for treating cancers with antibody drug conjugates (adc)
JP2021523158A5 (https=)
JP2025501978A5 (https=)
IL292706A (en) Type i interferon inhibition in systemic lupus erythematosus
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
KR20210122286A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
JP2020045351A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
CN111344043A (zh) 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法
AU2018228246A1 (en) Preventive or therapeutic agent for HTLV-1-associated myelopathy using low-dose anti-CCR4 antibody
TW202034925A (zh) Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
JP2023512084A5 (https=)
US20220184083A1 (en) Use of an agent capable of inhibiting the activation of mait cells for the treatment of obesity and obesity-related disorders
WO2020049534A1 (en) Sting agonist and combination therapy thereof for the treatment of cancer
IL292685A (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection